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Historical introduction
The development of the bisphosphonates from the preclinical stage to 
the most commonly used pharmaceutical compound for the prevention 
and treatment of osteoporosis-related fractures, is intimately linked to 
the person of Herbert Fleisch, late Swiss physician and scientist. His 
group found that plasma and urine contained inorganic pyrophosphate 
that inhibited calcium phosphate precipitation. Pyrophosphate had at 
that time been used industrially as an additive to washing powders to 
prevent the deposition of calcium carbonate in pipes. Pyrophosphate 
had limited clinical application as a result of rapid hydrolysis after 
oral administration. This led to the discovery of the bisphosphonates 
about 40 years ago. The bisphosphonates were shown to resist 
enzymatic hydrolysis and inhibit bone resorption.1 Since 1980 various 
new bisphosphonates have been developed. These drugs judged by 
the standards of evidence-based medicine were required to prove 
antifracture efficacy in large randomised placebo-controlled trials. 
Alendronate, risedronate, zoledronic acid and alendronate generic 
compounds are registered in South Africa for the prevention and 
treatment of osteoporosis-related fractures. The present discussion will 
be limited to these drugs. Collectively they represent in excess of 80% 
of the drugs used in this market segment. As with most drugs, utility is 
limited by various undesired side-effects. Recent concerns have been 
expressed regarding the long-term effect of the bisphosphonates on 
bone quality and bone strength. The aim of this article is to evaluate 
the present role of bisphosphonates in osteoporosis, taking into account 
strengths and weaknesses.
Chemistry and pharmacokinetics
The bisphosphonates are synthetic compounds derived from 
pyrophosphate, characterised by a P-C-P bond that is resistant to 
chemical and enzymatic hydrolysis. The basic P-C-P structure can be 
modified at the two lateral chains on the carbon atom or by esterifying 
the phosphate groups, leading to unique members of the family with 
distinct effects on bone metabolism. The ability of the compound to bind 
to bone surface seems to be dependent on the P-C-P bond while the side 
chain in combination with the P-C-P bond defines ability to inhibit bone 
resorption. The pharmacokinetic profile of oral alendronate has been 
studied extensively. Bisphosphonates are poorly absorbed, especially 
so in the presence of food or calcium. It is estimated that less than 
1% of alendronate is absorbed. This mainly occurs in the stomach by 
passive diffusion. Within hours of ingestion, 50% of the absorbed dose is 
excreted in the urine and 50% is deposited in bone. This happens rapidly 
resulting in a very short plasma half-life. The absorbed alendronate is 
buried under new layers of bone but will be released again when that 
area in which the alendronate is deposited is resorbed. The rate at which 
this occurs is determined by the rate of bone turnover. It is estimated 
that the total accumulation of alendronate after 10 years of standard 
dosing (10 mg daily) is 75 gram. If administration is stopped after 
10 years, bone remodelling will still result in skeletal release of 
alendronate equivalent to a daily oral dose of 2.5 mg.
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Mode of action
The bisphosphonates belong to the class of antiresorptive drugs. 
The ability of the bisphosphonates to inhibit osteoclast-induced bone 
resorption, to slow down bone turnover and to increase bone mass leads 
to an overall increase in bone strength that is reflected in antifracture 
efficacy in various clinical trials. Bisphosphonates reduce osteoclast 
numbers by the inhibition of recruitment of pre-osteoclasts and by 
the activation of apoptosis. Osteoclastic activity is inhibited. There is 
good evidence that the nitrogen-containing bisphosphonates inhibit 
the mevalonate pathway to inhibit protein prenylation. The effects of 
bisphosphonates on the osteoblast may include suppression of bone 
formation, especially after long-term use. The clinical relevance of this 
will be discussed later.
Strengths
Proof of efficacy
The nitrogen-containing bisphosphonates alendronate, risedronate 
and zoledronic acid have collectively been subjected to extensive 
randomised controlled clinical trials. Registration requires three years 
of treatment follow-up. All three drugs showed significant fracture 
protection against morphometric and clinical vertebral fracture2 as 
well as hip fracture.3 In terms of non-vertebral fractures, risedronate 
and zoledronic acid offered significant protection in primary analysis,4 
whereas the antifracture efficacy of alendronate in this subset was only 
significant in pooled analyses of FIT 1 and 2 studies.5 No head-to-head 
studies comparing the antifracture efficacy of these drugs to each other 
or to other treatment modalities have been done.
Variable mode of administration
Lack of compliance with medication is a reason for concern in the 
field of osteoporosis.6 The bisphosphonates offer variable modes of 
administration including variable oral and intravenous regimens that 
may increase compliance.
Cost
In South Africa, the cost of the originator, alendronate, has recently been 
lowered considerably. This was prompted by the availability of various 
cheaper generic alendronate. Concern has been expressed about the 
lack of proven clinical efficacy of the generic alendronate.7 A recent 
German study found original branded alendronate and risedronate to be 
significantly superior to the generics after one year in respect of bone 
mineral density (BMD). This may have been related to a higher incidence 
of gastrointestinal adverse events in the generic group, resulting in 
lower compliance.8  
Weaknesses
Lack of long-term fracture data
Proof of efficacy as regards fracture protection for longer than three 
years with bisphosphonates, is not as convincing as the three year data. 
A total of 247 patients on alendronate 10 mg daily were followed-up 
for 10 years.9 The primary endpoint was the change in BMD at the 
lumbar spine. Data on vertebral and clinical fracture were collected 
as safety endpoints. A mean increase in lumbar spine BMD of 13.7% 
(p < 0.001) versus baseline and a mean increase in trochanter hip BMD 
of 10.3% (p < 0.001) versus baseline were recorded. It was concluded 
that continuous treatment with alendronate 10 mg daily for 10 years 
sustained therapeutic effects on BMD and bone remodelling, with no 
lessening of antifracture efficacy over time. These conclusions should 
be interpreted with caution, considering the significant limitations of the 
study, especially regarding the ability of the study to monitor sustained 
fracture efficacy. A total of 136 patients completed risedronate therapy 
over seven years. The interpretation of the study is limited by the lack of 
a placebo group and small numbers.10 Data on zoledronic acid is limited 
to three years, but currently a three year extension is ongoing.
Lack of data in osteopenic patients
Treatment in osteoporosis has generally been directed at the patient 
with osteoporosis as defined by a BMD DXA T-score of < 2.5. It is now 
accepted that patients at risk of fracture, based on a combination of risk 
factors, such as incorporated in the FRAX model, should also be targeted 
for therapy.11 This implies that some patients with a BMD T-score of 
between -1.0 and -2.5 (osteopenia) may be considered for treatment. It 
is thus important to note that all trials involving the bisphosphonates and 
that have proven antifracture efficacy had excluded osteopenic patients 
or the data was adjusted post hoc to only include patients at a BMD of 
< -2.5. A post hoc subgroup analysis on risedronate, that pooled data from 
four different studies, claims efficacy for vertebral fracture protection in 
patients with osteopenia at the hip without vertebral fracture.12 It should 
be noted that in a randomised cotrolled trial risedronate failed to protect 
against hip fracture in the absence of hip BMD T-score < -3.5.
Side-effects
Gastrointestinal side-effects
Gastrointestinal side-effects such as nausea, vomiting, dyspepsia, gastric 
pain, diarrhoea and oesophageal erosions after the administration of 
standard dose oral bisphosphonates, are the most common side-effects 
reported by patients and are a significant reason for discontinuation of 
medication. The exact mechanism of action remains unknown, but the 
majority of oesophageal adverse events can be prevented by taking the 
drug with a full glass of water and by remaining upright and fasting 
for the next 30 minutes. The ability of oral bisphosphonate to irritate 
the gastrointestinal system has recently been highlighted by a report 
of 23 cases of oesophageal carcinoma in the USA in patients on oral 
bisphosphonates. Although no direct causal relationship has been 
established, it is recommended that caution be applied and that such 
therapy not be used in patients with Barrett oesophagus13 Less frequent 
dosing schedules, such as weekly or monthly, although at higher doses 
than daily, seem to have less gastric side-effects and to be better 
tolerated by patients.
Acute phase reaction after intravenous infusion
All bisphosphonates, when administered as an intravenous infusion, may 
result in transient post-infusion symptoms similar to those associated 
with mild influenza, including fever, myalgia, arthralgia, headache and 
nausea. These symptoms usually occur within 72 hours after the infusion 
and are mild-to-moderate in severity, generally resolve within one to 
four days and are much less likely to occur after later doses than after 
the first infusion. The mechanism underlying these symptoms is poorly 
understood. A recent study concluded that oral paracetamol or ibuprofen 
is effective in managing the transient flu-like symptoms associated with 
the administration of zoledronic acid IV and recommended that one of 
these agents be administered four hours after zoledronic acid infusion, 
particularly among bisphosphonate-naïve patients.14
Bone pain
Bone pain associated with the use of bisphosphonates is a side-effect 
often overlooked by physicians. The FDA in 2008 alerted physicians to 
the fact that some patients taking bisphosphonates may experience 
musculoskeletal pain within days, months or even years after initiating 
therapy. The pain may subside after discontinuation of the drug. The 
mechanism of action, incidence and predisposing factors are presently 
unknown.
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Atrial fibrillation 
A possible relationship between atrial fibrillation reported as a serious 
adverse event and the use of zoledronic acid 5 mg IV was reported by 
Black.15 It should be noted that the incidence of all reported events of 
atrial fibrillation was not significantly different between placebo and 
treated groups. The FDA, after reviewing the data of 19 687 patients 
treated with bisphosphonates and 18 358 patients on placebo, ruled that 
no clear association between the use of bisphosphonates and cardiac 
arrhythmias was apparent and advised that physicians should not alter 
present prescribing practices.
Osteonecrosis of the jaw
Osteonecrosis of the jaw (ONJ) is a rare condition characterised by 
necrotic exposed bone in the maxillofacial region. An association between 
the use of bisphosphonates and ONJ has been postulated for a few years 
and has caused much concern, especially amongst dentists. Most cases 
have been reported in patients with malignancies such as multiple 
myeloma or breast cancer treated with high doses of bisphosphonate 
therapy intravenously. It has rarely been reported in patients with 
postmenopausal osteoporosis or Paget disease of bone treated with 
standard doses of bisphosphonate therapy. Other predisposing factors 
are associated corticosteroid therapy, chemotherapy, head and neck 
irradiation, trauma, poor dental hygiene and dental surgery. A recent 
critical review of the literature reported that the aetiology of ONJ remains 
unknown and that to date no direct causal link to bisphosphonates has 
been established.16 Various bodies have developed guidelines for the 
prevention of ONJ. The Canadian guidelines recommend that in all 
oncology patients considered for bisphosphonate treatment a thorough 
dental examination including radiographs be completed prior to initiation 
of treatment. Any invasive treatment needs to be completed prior to 
therapy.17 Although much remains to be learned about this condition, 
including its true incidence in various patient populations, evidence to 
date suggests that ONJ poses a very small potential risk to the generally 
healthy patient being treated for osteoporosis in normal recommended 
doses.
Low energy subtrochanteric femur fractures
Odvina et al first reported concerns about potential over-suppression of 
bone turnover during long-term use of bisphosphonates. They reported 
on nine patients who sustained spontaneous non-vertebral fractures 
while on alendronate therapy, six of whom displayed either delayed or 
absent fracture healing for three months to two years during therapy. 
Histomorphometric analysis of the trabecular bone showed markedly 
suppressed bone formation in most patients.18 This report was followed 
by more cases that had several features in common. After a few years 
of bisphosphonate use (mostly alendronate) the patients presented 
with fractures of the femur shaft in the subtrochanteric region after 
minimal trauma. The fractures are sometimes preceded by bone pain. 
The first fracture is often followed by a subsequent fracture in the 
contra lateral femur. X-rays have a common pattern characterised by a 
simple transverse fracture line and hypertrophy of the diaphyseal cortex. 
This may result from propagation of a stress fracture whose repair is 
retarded by diminished osteoclast activity and impaired microdamage 
repair resulting from its prolonged use of bisphosphonates. It has 
been speculated that long-term bisphosphonate therapy may increase 
the risk of unusual long bone mid-shaft fractures due to prolonged 
suppression of bone turnover, which could lead to accumulation of 
microdamage and development of hypermineralised bone. At present, 
the scope of this complication in the larger context of patients receiving 
bisphosphonate therapy is not known, but appears to be small. In a large 
national observational register-based study, Abrahamsen et al reported 
that subtrochanteric femur fractures share the same epidemiology and 
treatment response of classical hip fractures and are best classified as 
osteoporotic fractures.19
The need for a drug holiday
The possibility of over-suppression of bone turnover and the possible 
risk of ONJ and low energy femur shaft fractures during extended usage 
has raised the question of how long bisphosphonate therapy should be 
continued. This question becomes even more relevant when considering 
the fact that bisphosphonates have the unique ability to accumulate in 
the skeleton. The only evidence to base any recommendation on is a 
study that compared the effects of discontinuing alendronate treatment 
after five years with continuing for ten years. Women who discontinued 
alendronate after five years showed a moderate decline in BMD and 
a gradual rise in biochemical markers but no higher fracture risk 
other than for clinical vertebral fractures compared with those who 
continued alendronate. These results suggest that for many women, 
discontinuation of alendronate for up to five years does not appear to 
significantly increase fracture risk. However, women at very high risk of 
clinical vertebral fractures may benefit by continuing beyond five years.20 
The design of this trial is unfortunately not robust enough to be definitive 
on the subject. Every clinician will have to decide in the individual patient 
on when to stop treatment or when to switch to other medication. The 
use of anabolic medication such as parathyroid hormone or a dual action 
agent such as strontium ranelate could be considered after five years of 
bisphosphonate treatment in a patient still at risk of fracture.
Conclusion
It is a remarkable feat that the bisphosphonates are market leaders in 
the field of osteoporososis, forty years after discovery.This is testimony 
of the considerable strengths of the bisphoshonates. It is unlikely that 
any of the possible side-effects as discussed will have a major impact 
on the utility of the bisphosphonates in the near future. A main driver of 
the future use of bisphosphonates will be cost-effectiveness.
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